📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial. (2023)

First Author: Compagnucci A

Attributed to: Paediatric and adolescent infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.eclinm.2023.102025

PubMed Identifier: 37304494

Publication URI: http://europepmc.org/abstract/MED/37304494

Type: Journal Article/Review

Volume: 60

Parent Publication: EClinicalMedicine

ISSN: 2589-5370